Contacto

SARS-CoV-2 Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing Antibody is a recombinant Human Monoclonal Antibody expressed in CHO cells against SARS-CoV-2/COVID-19 Spike Protein RBD (Omicron B.1.1.529 Variant). The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action. The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations which appear to increase the risk of reinfection compared to other variants of concern.

Proveedor

Abbexa

Reference

abx376490

Tested Applications

ELISA, WB

Reactivity

Virus

Host

Human

Status

RUO

Características de producto

tested_applications
ELISA, WB
reactivity
Virus
host
Human
Immunogen / Target
SARS-CoV-2
size_1
100 µg
clonality
Monoclonal
conjugation
Unconjugated
form
Liquid
purification
Purified by affinity chromatography.
storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
buffer
PBS, pH 7.5.
availability
Shipped within 5-12 working days
note
This product is for research use only.
isotype
IgG1
recomended_dilution
ELISA: 1/5000 - 1/10000, WB: 1/1000 - 1/2000. Optimal dilutions/concentrations should be determined by the end user